The anticytokine neuropeptide a-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: Comparisons with other anticytokine molecules

Anna Catania, Valeria Gerloni, Samuele Procaccia, Lorena Airaghi, Maria G. Manfredi, Claudia Lomater, Luca Grossi, James M. Lipton

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The aim of this study was to determine if the anticytokine neuropeptide α- melanocyte-stimulating hormone (a-MSH) occurs, along with interleukin 1 receptor antagonist (IL-lra) and soluble tumor necrosis factor receptor (sTNFr), in synovial fluid of patients with rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), or osteoarthritis. The data show that α-MSH does occur in the synovial fluid and its concentrations are greater in patients with RA than in those with osteoarthritis. Synovial fluid concentrations of IL-lra and sTNFr were likewise greater in RA. Further, concentrations of α-MSH, IL-l-ra, and sTNFr were greater in patients with polyarticular/systemic-onset JCA than in those with pauciarticular disease, that is in patients with greater joint inflammation. Concentrations of α-MSH were greater in synovial fluid than in plasma in a substantial proportion of patients, suggesting local production of the peptide; this is the first indication that the anticytokine molecule a-MSH is produced within a site of inflammation. Further, it appears that local production of α-MSH is induced particularly in those arthritic joints that have more intense inflammatory reactions. This finding, combined with previous evidence of the marked anti-inflammatory activity of α-MSH, suggests that the peptide acts locally to modulate proinflammatory influences in rheumatic diseases.

Original languageEnglish
Pages (from-to)321-328
Number of pages8
JournalNeuroImmunoModulation
Volume1
Issue number5
DOIs
Publication statusPublished - 1994

Fingerprint

Melanocyte-Stimulating Hormones
Synovial Fluid
Rheumatic Diseases
Neuropeptides
Tumor Necrosis Factor Receptors
Rheumatoid Arthritis
Juvenile Arthritis
Osteoarthritis
Joints
Inflammation
Peptides
Interleukin-1 Receptors
Arthritis
Anti-Inflammatory Agents

Keywords

  • Arthritis, juvenile chronic
  • Interleukin-1 receptor antagonist
  • Rheumatoid arthritis
  • Tumor necrosis factor receptor, soluble
  • α-Melanocyte stimulating hormone

ASJC Scopus subject areas

  • Endocrinology
  • Immunology
  • Endocrine and Autonomic Systems
  • Neurology
  • Neuroscience(all)

Cite this

The anticytokine neuropeptide a-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases : Comparisons with other anticytokine molecules. / Catania, Anna; Gerloni, Valeria; Procaccia, Samuele; Airaghi, Lorena; Manfredi, Maria G.; Lomater, Claudia; Grossi, Luca; Lipton, James M.

In: NeuroImmunoModulation, Vol. 1, No. 5, 1994, p. 321-328.

Research output: Contribution to journalArticle

Catania, Anna ; Gerloni, Valeria ; Procaccia, Samuele ; Airaghi, Lorena ; Manfredi, Maria G. ; Lomater, Claudia ; Grossi, Luca ; Lipton, James M. / The anticytokine neuropeptide a-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases : Comparisons with other anticytokine molecules. In: NeuroImmunoModulation. 1994 ; Vol. 1, No. 5. pp. 321-328.
@article{f017fdfa1eea4a47bb9e53cc7bf88394,
title = "The anticytokine neuropeptide a-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: Comparisons with other anticytokine molecules",
abstract = "The aim of this study was to determine if the anticytokine neuropeptide α- melanocyte-stimulating hormone (a-MSH) occurs, along with interleukin 1 receptor antagonist (IL-lra) and soluble tumor necrosis factor receptor (sTNFr), in synovial fluid of patients with rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), or osteoarthritis. The data show that α-MSH does occur in the synovial fluid and its concentrations are greater in patients with RA than in those with osteoarthritis. Synovial fluid concentrations of IL-lra and sTNFr were likewise greater in RA. Further, concentrations of α-MSH, IL-l-ra, and sTNFr were greater in patients with polyarticular/systemic-onset JCA than in those with pauciarticular disease, that is in patients with greater joint inflammation. Concentrations of α-MSH were greater in synovial fluid than in plasma in a substantial proportion of patients, suggesting local production of the peptide; this is the first indication that the anticytokine molecule a-MSH is produced within a site of inflammation. Further, it appears that local production of α-MSH is induced particularly in those arthritic joints that have more intense inflammatory reactions. This finding, combined with previous evidence of the marked anti-inflammatory activity of α-MSH, suggests that the peptide acts locally to modulate proinflammatory influences in rheumatic diseases.",
keywords = "Arthritis, juvenile chronic, Interleukin-1 receptor antagonist, Rheumatoid arthritis, Tumor necrosis factor receptor, soluble, α-Melanocyte stimulating hormone",
author = "Anna Catania and Valeria Gerloni and Samuele Procaccia and Lorena Airaghi and Manfredi, {Maria G.} and Claudia Lomater and Luca Grossi and Lipton, {James M.}",
year = "1994",
doi = "10.1159/000097183",
language = "English",
volume = "1",
pages = "321--328",
journal = "NeuroImmunoModulation",
issn = "1021-7401",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - The anticytokine neuropeptide a-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases

T2 - Comparisons with other anticytokine molecules

AU - Catania, Anna

AU - Gerloni, Valeria

AU - Procaccia, Samuele

AU - Airaghi, Lorena

AU - Manfredi, Maria G.

AU - Lomater, Claudia

AU - Grossi, Luca

AU - Lipton, James M.

PY - 1994

Y1 - 1994

N2 - The aim of this study was to determine if the anticytokine neuropeptide α- melanocyte-stimulating hormone (a-MSH) occurs, along with interleukin 1 receptor antagonist (IL-lra) and soluble tumor necrosis factor receptor (sTNFr), in synovial fluid of patients with rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), or osteoarthritis. The data show that α-MSH does occur in the synovial fluid and its concentrations are greater in patients with RA than in those with osteoarthritis. Synovial fluid concentrations of IL-lra and sTNFr were likewise greater in RA. Further, concentrations of α-MSH, IL-l-ra, and sTNFr were greater in patients with polyarticular/systemic-onset JCA than in those with pauciarticular disease, that is in patients with greater joint inflammation. Concentrations of α-MSH were greater in synovial fluid than in plasma in a substantial proportion of patients, suggesting local production of the peptide; this is the first indication that the anticytokine molecule a-MSH is produced within a site of inflammation. Further, it appears that local production of α-MSH is induced particularly in those arthritic joints that have more intense inflammatory reactions. This finding, combined with previous evidence of the marked anti-inflammatory activity of α-MSH, suggests that the peptide acts locally to modulate proinflammatory influences in rheumatic diseases.

AB - The aim of this study was to determine if the anticytokine neuropeptide α- melanocyte-stimulating hormone (a-MSH) occurs, along with interleukin 1 receptor antagonist (IL-lra) and soluble tumor necrosis factor receptor (sTNFr), in synovial fluid of patients with rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), or osteoarthritis. The data show that α-MSH does occur in the synovial fluid and its concentrations are greater in patients with RA than in those with osteoarthritis. Synovial fluid concentrations of IL-lra and sTNFr were likewise greater in RA. Further, concentrations of α-MSH, IL-l-ra, and sTNFr were greater in patients with polyarticular/systemic-onset JCA than in those with pauciarticular disease, that is in patients with greater joint inflammation. Concentrations of α-MSH were greater in synovial fluid than in plasma in a substantial proportion of patients, suggesting local production of the peptide; this is the first indication that the anticytokine molecule a-MSH is produced within a site of inflammation. Further, it appears that local production of α-MSH is induced particularly in those arthritic joints that have more intense inflammatory reactions. This finding, combined with previous evidence of the marked anti-inflammatory activity of α-MSH, suggests that the peptide acts locally to modulate proinflammatory influences in rheumatic diseases.

KW - Arthritis, juvenile chronic

KW - Interleukin-1 receptor antagonist

KW - Rheumatoid arthritis

KW - Tumor necrosis factor receptor, soluble

KW - α-Melanocyte stimulating hormone

UR - http://www.scopus.com/inward/record.url?scp=0028505291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028505291&partnerID=8YFLogxK

U2 - 10.1159/000097183

DO - 10.1159/000097183

M3 - Article

C2 - 8528899

AN - SCOPUS:0028505291

VL - 1

SP - 321

EP - 328

JO - NeuroImmunoModulation

JF - NeuroImmunoModulation

SN - 1021-7401

IS - 5

ER -